Stock Price Quote

DR. REDDY'S LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE6052.0042 (+0.7 %)
PREV CLOSE ( ) 6010.00
OPEN PRICE ( ) 6017.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9158
TODAY'S LOW / HIGH ( )5987.00 6071.00
52 WK LOW / HIGH ( )4383.4 6505.5
NSE6050.3539.5 (+0.66 %)
PREV CLOSE( ) 6010.85
OPEN PRICE ( ) 6005.85
BID PRICE (QTY) 6050.35 (21)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 408298
TODAY'S LOW / HIGH( ) 5985.05 6073.85
52 WK LOW / HIGH ( )4384.05 6505.9
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 24-02 1984
Management Info
K Satish Reddy - Chairman GV Prasad - Managing Director
Registered Office

Address 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040 - 4900 2900

Email mail@drreddys.com / shares@drreddys.com

Website www.drreddys.com

Registrars Details
Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York

NEWS

15Apr Dr. Reddy’s Laboratories’ arm to sell
Dr. Reddy’s Laboratories’ wholly owned subsidiary -- Dr. Reddy’s Laborat..
10Apr Dr. Reddy’s launches drug-free migrain
Dr. Reddy’s Laboratories has launched the drug-free non-invasive migrain..
05Apr Dr. Reddy's, Bayer sign marketing, dis
Dr. Reddy's Laboratories and Bayer have entered into a partnership to ma..
28Mar Dr. Reddy's Laboratories enters into e
Dr. Reddy's Laboratories has entered into an exclusive partnership with..
28Mar Dr. Reddy's Laboratories rises on ente
Dr. Reddy's Laboratories is currently trading at Rs. 6135.95, up by 88.3..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit475226128
Gross Profit 6319 38660
Operating Profit 883948061
Net Sales 41030169625

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  7519.90 (5.84%)
M.Cap ( in Cr)9647.95
NGL Fine-Chem (BSE)
peergroup  2264.35 (5.97%)
M.Cap ( in Cr)1398.92
Astrazeneca Pharma I (BSE)
peergroup  5288.60 (1.85%)
M.Cap ( in Cr)13221.50
Divi's Lab (BSE)
peergroup  3764.65 (1.32%)
M.Cap ( in Cr)99939.63
SMS Lifesciences (BSE)
peergroup  729.35 (6.09%)
M.Cap ( in Cr)220.50

Shareholding Pattern

MUTUAL FUNDS/UTI 8.22%
FI/BANKS/INSURANCE 7.99%
PROMOTERS 26.65%
NON-INSTITUTION 10.75%
GOVERNMENT 0%
FII 0%

About Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 6052. Its current market capitalisation stands at Rs 100958.41 Cr. In the latest quarter, company has reported Gross Sales of Rs. 169625 Cr and Total Income of Rs.175538 Cr. The company's management includes Alpna Hansraj Seth, Claudio Albrecht, Shikha Sharma, Leo Puri, Arun Kumar, Penny Wan, KP Krishnan, Kalpana Morparia, GV Prasad, K Satish Reddy, K Randhir Singh.

It is listed on the BSE with a BSE Code of 500124 , NSE with an NSE Symbol of DRREDDY and ISIN of INE089A01023. It's Registered office is at 8-2-337,Road No. 3,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are A Rama Chandra Rao & Co, Bharat S Raut & Co, BSR & Co, BSR & Co LLP, SR Batliboi & Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.